| Title |
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
|
|---|---|
| Published in |
Drug Design, Development and Therapy, March 2015
|
| DOI | 10.2147/dddt.s82007 |
| Pubmed ID | |
| Authors |
Runzhe Chen, Baoan Chen |
| Abstract |
Brentuximab vedotin is a promising antibody-drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refractory Hodgkin's lymphoma (HL), and it has also shown its advantages in other CD30-positive lymphomas. In this review, we focus on the structure, mechanisms, and pharmacokinetics of brentuximab vedotin. We also summarize clinical trials with brentuximab vedotin and make recommendations for brentuximab vedotin in the treatment of relapsed or refractory HL. |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 17% |
| Researcher | 6 | 17% |
| Student > Ph. D. Student | 5 | 14% |
| Student > Master | 4 | 11% |
| Student > Doctoral Student | 3 | 8% |
| Other | 4 | 11% |
| Unknown | 8 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 28% |
| Chemistry | 4 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Neuroscience | 2 | 6% |
| Computer Science | 2 | 6% |
| Other | 7 | 19% |
| Unknown | 9 | 25% |